2021年WHO胸膜肿瘤分类:自2015年分类以来的进展
2021年WHO胸膜与心包肿瘤分类相比2015年版有九项重要更新,包括胸膜与心包肿瘤合并为一章、高分化乳头状间皮瘤改名为高分化乳头状间皮肿瘤、局部和弥漫性间皮瘤不再加「恶性」前缀、新增原位间皮瘤、保留三种主要组织学亚型但更正式纳入结构模式和细胞/间质特征、引入上皮样弥漫性间皮瘤核分级、BAP1/EZH2/MTAP免疫组化有助鉴别良性间皮增生与间皮瘤、小活检中双相型间皮瘤诊断标准调整、以及弥漫性胸膜间皮瘤常见突变基因列表。
要点
- 胸膜与心包肿瘤合并为一章,原位间皮瘤被新增入分类。
- 高分化乳头状间皮瘤改名为高分化乳头状间皮肿瘤。
- 局部和弥漫性间皮瘤不再加「恶性」前缀。
核心结论
- 2021年WHO胸膜肿瘤分类在2015年版基础上有九项重要进展,涉及命名、诊断标准和预后相关组织学特征。
研究设计与样本
- 原文为2021年WHO胸膜与心包肿瘤分类的综述性解读,总结自2015年分类以来的主要变化。
主要发现
- 胸膜和心包肿瘤合并为一章,而2015年WHO将心包肿瘤与心脏肿瘤归为一章。
- 高分化乳头状间皮瘤改名为高分化乳头状间皮肿瘤,因证据显示这些肿瘤行为相对惰性。
- 局部和弥漫性间皮瘤不再包括「恶性」作为前缀。
- 原位间皮瘤被新增入2021年分类,因可通过免疫组化BAP1和/或MTAP缺失及/或荧光原位杂交CDKN2A纯合缺失识别。
- 三种主要组织学亚型(上皮样、双相型、肉瘤样)保持不变,但结构模式及细胞学和间质特征基于其预后意义被更正式纳入分类。
关键数值与推荐
- 原位间皮瘤可通过免疫组化BAP1和/或MTAP缺失及/或荧光原位杂交CDKN2A纯合缺失识别。
- 小活检中双相型间皮瘤可诊断,即使一种成分量少于10%。
- 上皮样弥漫性间皮瘤核分级被引入,推荐在病理报告中记录。
- BAP1、EZH2和MTAP免疫组化有助区分良性间皮增生与间皮瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; (2) well-differentiated papillary mesothelioma has been renamed well-differentiated papillary mesothelial tumor given growing evidence that these tumors exhibit relatively indolent behavior; (3) localized and diffuse mesothelioma no longer include the term "malignant" as a prefix; (4) mesothelioma in situ has been added to the 2021 classification because these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by fluorescence in situ hybridization; (5) the three main histologic subtypes (i.e., epithelioid, biphasic, and sarcomatoid) remain the same but architectural patterns and cytologic and stromal features are more formally incorporated into the 2021 classification on the basis of their prognostic significance; (6) nuclear grading for epithelioid diffuse mesothelioma is introduced, and it is recommended to record this and other histologically prognostic features in pathology reports; (7) BAP1, EZH2, and MTAP immunohistochemistry have been found to be useful in separating benign mesothelial proliferations from mesothelioma; (8) biphasic mesothelioma can be diagnosed in small biopsies having both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and (9) the most frequently altered genes in diffuse pleural mesothelioma include BAP1, CDKN2A, NF2, TP53, SETD2, and SETDB1.
引用
- Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022. PMID: 35026477. doi:10.1016/j.jtho.2021.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。